Physician profile
Robert G Carter
NPI 1922192418
$5,107.64
in general payments reported to CMS, 2019-2025
29 companies · $1,100 in 2025
The $1,100 reported for 2025 was more than what 86% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $926 · 2020: $240 · 2021: $737 · 2022: $652 · 2023: $970 · 2024: $483 · 2025: $1,100.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,871 · Consulting Fee: $682.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,870.90 |
| Consulting Fee | $682.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $852.40 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Seqirus USA INC | $682.00 | 2023 | |
| Abbvie INC. | $629.95 | 2021-2024 | Vraylar |
| Merck Sharp & Dohme LLC | $456.98 | 2019-2023 | Verquvo, Vaxneuvance, Gardasil 9 |
| Pfizer INC. | $418.68 | 2019-2025 | |
| Vanda Pharmaceuticals INC. | $334.93 | 2025 | Fanapt |
| Allergan, INC. | $282.98 | 2019-2020 | |
| Amgen INC. | $281.07 | 2021-2025 | Repatha |
| Astrazeneca Pharmaceuticals LP | $228.65 | 2019-2025 | Airsupra, Farxiga |
| E.R. Squibb & Sons, L.L.C. | $172.73 | 2019 | |
| Indivior INC. | $162.68 | 2019-2023 | Sublocade |
| Abiomed | $122.43 | 2025 | |
| Exact Sciences Corporation | $81.74 | 2023-2025 | Cologuard Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $69.65 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $58.43 | 2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Orexo US, INC. | $43.45 | 2019 | |
| Circassia INC. | $32.07 | 2019 | |
| Jazz Pharmaceuticals INC. | $26.75 | 2024 | |
| Braeburn INC. | $24.00 | 2023 | Brixadi |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $21.07 | 2021 | |
| Janssen Pharmaceuticals, INC | $20.86 | 2024 | Spravato |
| Avadel Cns Pharmaceuticals, LLC | $19.68 | 2024 | Lumryz |
| Medtronic, INC. | $18.37 | 2022 | |
| Sk Life Science, INC. | $18.06 | 2021 | |
| Nevro Corp. | $17.91 | 2024 | Senza |
| Idorsia Pharmaceuticals US INC | $17.82 | 2023 | Quviviq |
| Glaxosmithkline, LLC. | $12.30 | 2021 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Carter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.